Gossamer Bio Announces Presentations at the European Respiratory Society Congress 2025

- One Oral and Four Poster Presentations Highlight Seralutinib's Potential Across Pulmonary Hypertension and Fibrotic Lung Disease -

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27 ^th through October 1 ^st in Amsterdam, Netherlands and online. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.

ERS 2025 Presentation Details:

Session Type: Oral Presentation Session Title: From omics to targets: emerging insights into chronic pulmonary disease mechanisms (Session 94) Session Date & Time: September 28 th 9:30am 10:45am CEST Location: Amtrium Abstract Number: OA1201 Presentation Title: Seralutinib targets fibrotic pathways in IPF: Evidence from single‑cell transcriptomics Presenter: Dr. Rui Benfeitas (Chiesi Group)

Session Type: Poster Presentation
Session Title: Preclinical insights into rare diseases (Session 75)
Session Date & Time: September 28 ^th , 8:00am – 9:30am CEST
Location: PS-7
Abstract Number: PA1039
Presentation Title: Seralutinib demonstrates in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
Presenter: Dr. Zhaoqing Ding (Gossamer Bio)

Session Type: Poster Presentation
Session Title: Translational studies in interstitial lung disease of known causes (Session 149)
Session Date & Time: September 28 ^th , 12:30pm – 2:00pm CEST
Location: PS-34
Abstract Number: PA1864
Presentation Title: Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models
Presenter: Dr. Ravikumar Sitapara (Gossamer Bio)

Session Type: Poster Presentation
Session Title: Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments (Session 423)
Session Date & Time: September 30 ^th , 8:00am – 9:30am CEST
Location: PS-38
Abstract Number: PA5143
Presentation Title: Seralutinib increases small pulmonary artery vessel volume and reduces vessel wall remodeling: Insights from AI-driven CT imaging analysis
Presenter: Dr. Raúl San José Estépar (Brigham Women's Hospital)

Session Type: Poster Presentation
Session Title: Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments (Session 423)
Session Date & Time: September 30 ^th , 8:00am – 9:30am CEST
Location: PS-38
Abstract Number: PA5144
Presentation Title: Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
Presenter: Dr. Zhaoqing Ding (Gossamer Bio)

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250922224756/en/

For Investors and Media
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com